Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis

Trial Profile

A Phase 1b/2 Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs KZR 616 (Primary) ; Mycophenolate mofetil; Prednisolone
  • Indications Lupus nephritis; Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors Kezar Life Sciences
  • Most Recent Events

    • 05 Dec 2018 According to a Kezar Life Sciences media release, phase 2 trial in lupus nephritis patients expected to initiate during the first half of 2019.
    • 31 Aug 2018 Biomarkers information updated
    • 09 Aug 2018 According to a Kezar Life Sciences media release, the top-line results from the initial two cohorts of the Phase 1b are expected in the first half of 2019 and remain on track to initiate our first randomized trial in LN, in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top